About
Bonus BioGroup is a product-focused biotechnology company applying proprietary technology to supply tissue-regenerating, viable bone grafts. The company develops cell therapy and tissue-engineering products based on autologous bone implants that enable efficient bone transplantation and provide cell-based bone replacement for repairing bone lesions. Bonus BioGroup is the developer of BonoFill, a method for growing high-density 3D bone grafts based on multicell 3D cultures. BonoFill is derived from the patients own cells and constructed from a variety of cells grown in multiple layers within a bioreactor system. BonoFills technology enables the construction of bone grafts outside of the human body (ex vivo) and promotes graft acceptance by the patients body following transplantation. It also allows growth of a human tissue graft tailored to the biological, physical, and clinical needs of each patient, without incurring immune reactions or graft rejection.
Funding history · 3 rounds · $25.6M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Bonus BioGroup become a publicly traded company?
- Bonus BioGroup went public on the TASE in February 2012.
- What significant regulatory approval did Bonus BioGroup receive in February 2025?
- In February 2025, Bonus BioGroup announced that it received U.S. Food and Drug Administration (FDA) Clearance of an Investigational New Drug (IND) Application for its MesenCure™ Phase III Clinical Study in Respiratory Distress.
- What was a key development for Bonus BioGroup's MesenCure treatment in January 2022?
- In January 2022, Bonus BioGroup submitted Phase-II trial results for MesenCure, a treatment for severe COVID-19, to the Israeli Ministry of Health.
- What was a notable clinical trial expansion for Bonus BioGroup in August 2021?
- In August 2021, Bonus BioGroup received approval to expand Phase-II clinical trials for its COVID-19 treatment to medical centers across Israel.
- What patent did Bonus BioGroup register in March 2021?
- In March 2021, Bonus BioGroup registered a patent for the development of an artificial blood vessel network.
- What was a significant achievement for Bonus BioGroup in January 2024?
- In January 2024, Bonus BioGroup became the first Israeli company to win the Advanced Therapies Award globally.
- What was the total amount raised by Bonus BioGroup through funding rounds?
- Bonus BioGroup has raised a total of $25.6 million through funding rounds, including PIPE rounds in September 2018, January 2021, and February 2021 with investors like SIBF VC.
- What was a key grant received by Bonus BioGroup and when?
- In January 2015, Bonus BioGroup received a grant of $1.6 million from the IIA.
- What significant board appointment did Bonus BioGroup make in July 2025?
- In July 2025, Bonus BioGroup appointed Professor Edwin M. Horwitz, MD, PhD, a renowned cell therapy leader, to its Advisory Board.